Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Structure Therapeutics Inc (GPCR)

Structure Therapeutics Inc (GPCR)
15.19 x 1 15.90 x 5
Post-market by (Cboe BZX)
15.12 -1.21 (-7.41%) 04/04/25 [NASDAQ]
15.19 x 1 15.90 x 5
Post-market 15.00 -0.12 (-0.79%) 17:40 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
14.88
Day High
15.95
Open 15.73
Previous Close 16.33 16.33
Volume 949,900 949,900
Avg Vol 847,470 847,470
Stochastic %K 11.78% 11.78%
Weighted Alpha -74.83 -74.83
5-Day Change -4.65 (-23.52%) -4.65 (-23.52%)
52-Week Range 14.88 - 62.74 14.88 - 62.74
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 867,026
  • Shares Outstanding, K 57,343
  • Annual Sales, $ 0 K
  • Annual Income, $ -122,530 K
  • EBIT $ -158 M
  • EBITDA $ -176 M
  • 60-Month Beta -1.35
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.12

Options Overview Details

View History
  • Implied Volatility 107.78% ( +17.37%)
  • Historical Volatility 94.83%
  • IV Percentile 89%
  • IV Rank 29.82%
  • IV High 224.41% on 05/31/24
  • IV Low 58.22% on 08/23/24
  • Put/Call Vol Ratio 0.60
  • Today's Volume 160
  • Volume Avg (30-Day) 499
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 16,992
  • Open Int (30-Day) 17,159

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.24
  • Number of Estimates 7
  • High Estimate -0.17
  • Low Estimate -0.31
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -26.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.88 +1.61%
on 04/04/25
Period Open: 22.49
23.57 -35.85%
on 03/06/25
-7.37 (-32.77%)
since 03/04/25
3-Month
14.88 +1.61%
on 04/04/25
Period Open: 27.76
31.72 -52.33%
on 01/31/25
-12.64 (-45.53%)
since 01/03/25
52-Week
14.88 +1.61%
on 04/04/25
Period Open: 39.30
62.74 -75.90%
on 06/03/24
-24.18 (-61.53%)
since 04/04/24

Most Recent Stories

More News
The State of Weight Loss Drugs

In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss:

GIS : 59.61 (-2.23%)
VKTX : 22.62 (-6.61%)
NVO : 62.55 (-6.78%)
HIMS : 25.99 (-7.15%)
LLY : 738.21 (-6.45%)
CAG : 26.68 (-0.37%)
GPCR : 15.12 (-7.41%)
ISRG : 451.58 (-8.70%)
PFE : 22.97 (-5.43%)
Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights

GPCR : 15.12 (-7.41%)
Why Structure Therapeutics Stock Was Stumbling This Week

The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics (NASDAQ: GPCR), was a victim...

LLY : 738.21 (-6.45%)
GPCR : 15.12 (-7.41%)
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

GPCR : 15.12 (-7.41%)
AI Pharma: 2 Paths to AI-Powered Drug Investment

AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.

LLY : 738.21 (-6.45%)
GPCR : 15.12 (-7.41%)
SDGR : 18.03 (-4.45%)
NVS : 105.85 (-5.71%)
RXRX : 4.24 (-11.85%)
Structure Therapeutics Inc. Advances ACCG-2671 as Lead Oral Amylin-Based Drug Candidate with Promising Preclinical Results

ACCG-2671 shows promise for weight loss and safety, with Phase 1 trials planned by late 2025.Quiver AI SummaryStructure Therapeutics Inc. has announced the selection of its lead oral small molecule amylin...

GPCR : 15.12 (-7.41%)
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

GPCR : 15.12 (-7.41%)
2 ‘Monster’ Stocks to Snap Up Before 2025

Analysts at Jefferies have identified Metagenomi and Structure Therapeutics as two "monster" stocks in the biotech sector, with potential gains of up to 1,000%.

GPCR : 15.12 (-7.41%)
MGX : 1.4100 (+11.90%)
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

GPCR : 15.12 (-7.41%)
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

GPCR : 15.12 (-7.41%)

Business Summary

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat chronic metabolic and pulmonary diseases with unmet medical needs. Structure Therapeutics Inc. is based in SAN FRANCISCO.

See More

Key Turning Points

3rd Resistance Point 16.82
2nd Resistance Point 16.39
1st Resistance Point 15.75
Last Price 15.12
1st Support Level 14.68
2nd Support Level 14.25
3rd Support Level 13.61

See More

52-Week High 62.74
Fibonacci 61.8% 44.46
Fibonacci 50% 38.81
Fibonacci 38.2% 33.16
Last Price 15.12
52-Week Low 14.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades